Equities research analysts expect Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Rating) to report earnings of $0.46 per share for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Maravai LifeSciences’ earnings, with estimates ranging from $0.39 to $0.48. Maravai LifeSciences posted earnings per share of $0.44 during the same quarter last year, which would suggest a positive year-over-year growth rate of 4.5%. The business is expected to announce its next quarterly earnings results on Monday, January 1st.
According to Zacks, analysts expect that Maravai LifeSciences will report full-year earnings of $1.85 per share for the current financial year, with EPS estimates ranging from $1.80 to $1.88. For the next year, analysts expect that the business will report earnings of $1.24 per share, with EPS estimates ranging from $0.96 to $1.52. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Maravai LifeSciences.
Maravai LifeSciences (NASDAQ:MRVI – Get Rating) last issued its quarterly earnings results on Thursday, May 5th. The company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.43 by $0.11. The company had revenue of $244.30 million for the quarter, compared to the consensus estimate of $232.29 million. Maravai LifeSciences had a net margin of 25.25% and a return on equity of 96.51%. The firm’s revenue was up 64.8% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.26 EPS.
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.
And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
MRVI has been the subject of several research reports. Morgan Stanley lowered their price target on shares of Maravai LifeSciences from $59.00 to $54.00 and set an “overweight” rating for the company in a research report on Friday, February 25th. Zacks Investment Research lowered shares of Maravai LifeSciences from a “buy” rating to a “hold” rating in a research note on Wednesday, May 11th. Finally, Robert W. Baird dropped their price target on shares of Maravai LifeSciences from $48.00 to $40.00 in a research report on Friday, May 6th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, Maravai LifeSciences has a consensus rating of “Buy” and a consensus price target of $48.40.
Hedge funds have recently made changes to their positions in the stock. Select Equity Group L.P. lifted its position in shares of Maravai LifeSciences by 69.5% during the 4th quarter. Select Equity Group L.P. now owns 20,542,503 shares of the company’s stock worth $860,731,000 after buying an additional 8,420,492 shares during the last quarter. Massachusetts Financial Services Co. MA increased its stake in Maravai LifeSciences by 44.4% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 8,003,021 shares of the company’s stock valued at $335,326,000 after buying an additional 2,459,692 shares during the period. BlackRock Inc. grew its stake in shares of Maravai LifeSciences by 30.7% during the 4th quarter. BlackRock Inc. now owns 6,053,047 shares of the company’s stock worth $253,622,000 after purchasing an additional 1,420,288 shares during the period. Marshall Wace LLP grew its stake in shares of Maravai LifeSciences by 1,911.8% during the 3rd quarter. Marshall Wace LLP now owns 1,488,016 shares of the company’s stock worth $73,032,000 after purchasing an additional 1,414,052 shares during the period. Finally, Ardevora Asset Management LLP acquired a new position in shares of Maravai LifeSciences during the 4th quarter worth $59,130,000. Hedge funds and other institutional investors own 50.18% of the company’s stock.
Shares of MRVI opened at $32.21 on Wednesday. The company has a 50 day moving average price of $33.27 and a 200-day moving average price of $35.03. Maravai LifeSciences has a fifty-two week low of $23.16 and a fifty-two week high of $63.55. The stock has a market capitalization of $8.22 billion, a PE ratio of 20.26 and a beta of 0.76. The company has a debt-to-equity ratio of 0.80, a quick ratio of 6.55 and a current ratio of 7.14.
Maravai LifeSciences Company Profile (Get Rating)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Further Reading
Get a free copy of the Zacks research report on Maravai LifeSciences (MRVI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should you invest $1,000 in Maravai LifeSciences right now?
Before you consider Maravai LifeSciences, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Maravai LifeSciences wasn’t on the list.
While Maravai LifeSciences currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com
